FGEN Stock Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.20|
|52 Week High||US$30.12|
|52 Week Low||US$7.81|
|1 Month Change||-22.17%|
|3 Month Change||-41.18%|
|1 Year Change||-55.66%|
|3 Year Change||-74.47%|
|5 Year Change||-65.80%|
|Change since IPO||-58.18%|
Recent News & Updates
|FGEN||US Biotechs||US Market|
Return vs Industry: FGEN underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: FGEN underperformed the US Market which returned -10.4% over the past year.
|FGEN Average Weekly Movement||11.0%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: FGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: FGEN's weekly volatility (11%) has been stable over the past year.
About the Company
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy.
FibroGen Fundamentals Summary
|FGEN fundamental statistics|
Is FGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FGEN income statement (TTM)|
|Cost of Revenue||US$355.09m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.02|
|Net Profit Margin||-109.22%|
How did FGEN perform over the long term?See historical performance and comparison
Is FibroGen undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FGEN ($9.24) is trading below our estimate of fair value ($15.03)
Significantly Below Fair Value: FGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FGEN is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (1.4x).
How is FibroGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FGEN's revenue (18.9% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: FGEN's revenue (18.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FGEN's Return on Equity is forecast to be high in 3 years time
How has FibroGen performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FGEN is currently unprofitable.
Growing Profit Margin: FGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FGEN is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare FGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: FGEN has a negative Return on Equity (-158.12%), as it is currently unprofitable.
How is FibroGen's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FGEN's short term assets ($524.4M) exceed its short term liabilities ($255.4M).
Long Term Liabilities: FGEN's short term assets ($524.4M) exceed its long term liabilities ($312.5M).
Debt to Equity History and Analysis
Debt Level: FGEN has more cash than its total debt.
Reducing Debt: FGEN's debt to equity ratio has reduced from 10% to 9.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FGEN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: FGEN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 2.8% each year.
What is FibroGen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FGEN has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Enrique Conterno (54 yo)
Mr. Enrique A. Conterno is the Chief Executive Officer and Director at FibroGen, Inc. since January 6, 2020. He served as President of Lilly USA from January 2017 to 2019. Mr. Conterno served as President...
CEO Compensation Analysis
Compensation vs Market: Enrique's total compensation ($USD10.39M) is above average for companies of similar size in the US market ($USD3.88M).
Compensation vs Earnings: Enrique's compensation has been consistent with company performance over the past year.
Experienced Management: FGEN's management team is considered experienced (4 years average tenure).
Experienced Board: FGEN's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
FibroGen, Inc.'s employee growth, exchange listings and data sources
- Name: FibroGen, Inc.
- Ticker: FGEN
- Exchange: NasdaqGS
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$862.069m
- Shares outstanding: 93.30m
- Website: https://www.fibrogen.com
Number of Employees
- FibroGen, Inc.
- 409 Illinois Street
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.